All News

Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy

Jack Cush, MD

A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early recognition can lead to effective management that allows continuation of cancer therapy. 

Read Article
Gout pills injection

Managing Gout in CKD Patients

Jack Cush, MD

A current review article addressed the management of gout patients with chronic kidney disease (CKD).  This full read review addresses the epidemiology, challenges, treatment decisions and outcomes. 

Read Article
RA erosions bone ACR

b/ts-DMARDs Do Not Arrest Bone Loss in RA

Jack Cush, MD

In RA, the goal is to control or arrest inflammation such that articular and bony damage is halted. While we have many effective therapies, it is not clear that biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) can prevent or improve osteoporosis outcomes in RA. A current real-world study showed that 1 year of b/tsDMARDs use did not arrest osteoporosis progression.

Read Article
antibody (Keep)

NEJM: Obinutuzumab in Active Systemic Lupus Erythematosus

Jack Cush, MD

A phase 3 trial of obinutuzumab, an anti-CD20 monoclonal antibody, showed potent B-cell depletion and clinical efficacy active systemic lupus erythematosus without evidence of nephritis.

Read Article
Eye exam 2

Long-Term Hydroxychloroquine Retinopathy Risk

MedPage Today

About one in 18 patients taking hydroxychloroquine (HCQ) for 15 years develop retinal damage, a new meta-analysis indicated.

Read Article
FDA%20approved.jpg (keep)

TYK2 Inhibitor Deucravacitinib FDA Approved for Psoriatic Arthritis

Jack Cush, MD

On Friday, March 6th, the FDA approved deucravacitinib (Sotyktu) for the treatment of adults with active psoriatic arthritis (PsA) based on the results of the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical trials.

Read Article
RheumNow Podcast square

UBER Rheumatology Ride (3.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Read Article
Stiffness,hand,MCP,joint,pain

Open-access Arthralgia Clinics

Jack Cush, MD

The early diagnosis in inflammatory arthritis (IA), particularly rheumatoid arthritis (RA), hinges on efficient referral and screening of arthralgia patients.

Read Article
Gout.T2T.jpg

Treat-to-Target and Cardiovascular Benefits in Gout

Jack Cush, MD

A new user cohort study of 109 504 gout patients, achieving a serum urate level less than 6 mg/dL, was associated with a significantly lower risk of cardiovascular events.

Read Article
Managing Gout in CKD Patients A current review article addressed the management of gout patients with chronic kidney disease (CKD). This full read review addresses the epidemiology, challenges, treatment decisions, and outcomes. https://t.co/ND0cspcmDd https://t.co/HI55D5koZj

Links:

Dr. John Cush RheumNow ( View Tweet)
Prebiotic fibre improves knee OA. Study of 117 older adults w/ KOA Rx w/ 6wks of inulin (fibre) or Physiotherapy exercise (PSE) or both vs PBO. Both Inulin & PSE signif improved pain & PSE vs PBO ( −1.11 to -2.5; p <0.045); inulin also improved pain sensitivity & grip strength https://t.co/Efic4mru1i
Dr. John Cush RheumNow ( View Tweet)
Swiss study of 1st TNFi efficacy in 3324 axial spondy (axSpA) (≤1 yr=very early Dz,441; 1-2 yrs =early axSpA, 218; >2 yrs=establi axSpA, 2575). After adjusting for age/sex, B27, etc, no signif. difference seen when TNFi started regarding later outcomes: TNFi retention, or ASDAS https://t.co/1EaP8UOsVt
Dr. John Cush RheumNow ( View Tweet)
Poor sleep increases risk of #RA. English Longitudinal Study of Ageing. RA risk was signif. higher in those with moderate sleep quality (SQ) (HR 1.23) or poor SQ (HR 1.50), cmpared to good SQ. Partly mediated by depression https://t.co/kTbCUHeIGi https://t.co/6CD5tsKDdA

Links:

Dr. John Cush RheumNow ( View Tweet)
Muscular strength is a resilience marker relevant to function. A prospective cohort study of 5472 women (mean 79 yrs), showed that greater muscular strength (grip strength, chair stand time) was assoc w/ lower mortality (HR 0.85- 0.67) https://t.co/HEO4r2cdmS https://t.co/Ada3Bnrt0Z

Links:

Dr. John Cush RheumNow ( View Tweet)
Observational study of 42 Mexican lupus nephritis pts on Immunosuppressives + Calcineurin Inhibitors (CNIs) @ 12 mos complete & partial responses seen in 26% & 36%, w/ signif reduction in proteinuria (2.89 vs 0.72 g/d, p < .001), & transient decrease in eGFR at 12 mo (109 vs 114) https://t.co/Het4GKaTmv
Dr. John Cush RheumNow ( View Tweet)
Open-access Arthralgia Clinics The early diagnosis of IA, particularly RA, hinges on efficient referral and screening of arthralgia patients. Yet most rheumatology practices are ill-equipped or don't have EACs. This report describes the use of an OAC to manage primary care https://t.co/8ut6LkIUEX
Dr. John Cush RheumNow ( View Tweet)
Missed #RheumNowLive 2026? The full meeting is now available On Demand. ✔ 2 days of clinical updates ✔ Expert faculty panels ✔ Speaker slides ✔ Pre-learn modules Watch anytime for $250. Learn from the meeting that kicks off the year in rheumatology. 🔗 Access here: https://t.co/jRvmbf87cs
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 8 articles, 2655 gout pts shows that ELEVATED neutrophil-to-lymphocyte ratio (NLR; SMD: 0.75; 95% CI: 0.48–1.03) and platelet-lymphocyte ratio (PLR; SMD: 0.52; 95% CI: 0.24–0.79) showed significant value in predicting acute gout attacks https://t.co/RaArPdoc2s https://t.co/Qi2WDSPlde

Links:

Dr. John Cush RheumNow ( View Tweet)
Observational study of 42 Mexican lupus nephritis pts on Immunosuppressives + Calcineurin Inhibitors (CNIs) @ 12 mos complete & partial responses seen in 26% & 36%, w/ signif reduction in proteinuria (2.89 vs 0.72 g/d, p < .001), & transient decrease in eGFR at 12 mo (109 vs 114) https://t.co/G70POtJwhS
Dr. John Cush RheumNow ( View Tweet)
BREAKING NEWS: How many patients with RA achieve and maintain remission with a JAKi? Find out in the RheumNow poster hall with data from the latest real-world study of long-term RA remission. Sponsored by AbbVieMedical Affairs + Health Impact. https://t.co/PPYVfz3tuC https://t.co/Boq8V3qqFp

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×